Voices
Arndt Vogel
Arndt Vogel/X

Arndt Vogel: A Pooled analysis of NIFTY and NALIRICC trials

Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Medical University of Hanover, shared a post on X about a recent article he and colleagues authored:

“Now fully published: Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC.

Nal-IRI with 5-FU/LV improves PFS and ORR.”

Arndt Vogel

Title: Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials

Authors: Changhoon Yoo, Anna Saborowski, Jaewon Hyung, Patrick Wenzel, Ilhwan Kim, Henning Wege, Kyu-pyo Kim, Gunnar Folprecht, Baek-Yeol Ryoo, Phillip Schütt, Jaekyung Cheon, Thorsten Götze, Hyewon Ryu, Ji Sung Lee, Arndt Vogel

Read the Full Article in Journal of Hepatology.

Arndt Vogel

More posts featuring biliary tract cancer on OncoDaily.

Anna Saborowski Arndt Vogel Baek-Yeol Ryoo Biliary tract cancer cancer Changhoon Yoo Gunnar Folprecht Henning Wege Hyewon Ryu Ilhwan Kim Jaekyung Cheon Jaewon Hyung Ji Sung Lee Kyu-pyo Kim NALIRICC NIFTY OncoDaily Oncology Patrick Wenzel Phillip Schütt Thorsten Götze